top of page
Executive Spotlights

Aiolos Bio Launches with $245M Series A Investment

San Francisco and London, October 24, 2023 (Business Wire) -- Aiolos Bio, Inc. officially launches as a clinical-stage biopharmaceutical company, committed to addressing unmet medical needs in respiratory and inflammatory conditions. The company secures an oversubscribed $245 million in Series A funding.

Read full article here.

Recent Posts

See All

R3 Vascular Raises $87M in Series B Financing

Mountain View, CA, May 20, 2024 (FinSMEs) -- R3 Vascular, a medical device firm headquartered in California, secured $87 million in Series B financing. The funding round, spearheaded by Deerfield Ma


Life Science Headlines
bottom of page